Biocryst Pharmaceuticals Inc (BCRX)
SG&A Expenses
$63.98M
Quarterly · Period ending: · USD
BCRX SG&A Expenses
Latest reported$63.98Mperiod ending
Latest reported$63.98Mperiod ending
BCRX Quarterly SG&A Expenses ($500.00K → $63.98M)
Quarterly SG&A Expenses
High-resolution chart · PNG
BCRX sg&a expenses history
Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | SG&A Expenses (USD) |
|---|---|
| 63,976,000 | |
| 94,554,000 | |
| 95,781,000 | |
| 83,014,000 | |
| 87,383,000 | |
| 82,469,000 | |
| 80,470,000 | |
| 65,084,000 | |
| 61,249,000 | |
| 59,491,000 | |
| 64,382,000 | |
| 50,648,000 | |
| 50,997,000 | |
| 47,867,000 | |
| 50,153,000 | |
| 36,919,000 | |
| 38,017,000 | |
| 34,282,000 | |
| 35,387,000 | |
| 34,992,000 | |
| 26,325,000 | |
| 22,114,000 | |
| 20,986,000 | |
| 17,195,000 | |
| 13,883,000 | |
| 15,865,000 | |
| 10,489,000 | |
| 11,735,000 | |
| 8,659,000 | |
| 6,238,000 | |
| 4,490,000 | |
| 7,923,000 | |
| 9,492,000 | |
| 7,609,000 | |
| 4,698,000 | |
| 3,343,000 | |
| 2,834,000 | |
| 3,058,000 | |
| 2,561,000 | |
| 2,756,000 | |
| 2,724,000 | |
| 3,212,000 | |
| 2,721,000 | |
| 2,731,000 | |
| 3,534,000 | |
| 4,061,000 | |
| 2,048,000 | |
| 1,812,000 | |
| 2,013,000 | |
| 1,588,000 | |
| 1,270,000 | |
| 1,337,000 | |
| 1,231,000 | |
| 1,382,000 | |
| 1,929,000 | |
| 1,705,000 | |
| 1,609,000 | |
| 1,781,000 | |
| 1,055,000 | |
| 3,282,000 | |
| 4,003,000 | |
| 4,002,000 | |
| 3,379,581 | |
| 3,793,000 | |
| 3,209,000 | |
| 3,797,000 | |
| 3,647,187 | |
| 3,064,000 | |
| 2,313,000 | |
| 2,457,000 | |
| 2,376,227 | |
| 2,471,000 | |
| 2,666,000 | |
| 2,886,000 | |
| 2,485,962 | |
| 2,595,000 | |
| 2,013,000 | |
| 2,372,000 | |
| 1,630,373 | |
| 1,599,000 | |
| 1,384,000 | |
| 1,495,000 | |
| 1,468,323 | |
| 795,000 | |
| 727,000 | |
| 696,000 | |
| 897,316 | |
| 728,000 | |
| 926,000 | |
| 660,000 | |
| 1,125,000 | |
| 526,000 | |
| 553,000 | |
| 607,000 | |
| 559,804 | |
| 655,000 | |
| 871,000 | |
| 768,000 | |
| 1,007,089 | |
| 689,000 |